Sionna Therapeutics, Inc. Common Stock Total Assets
Sionna Therapeutics, Inc. Common Stock total assets. Based on the latest financial reports, Sionna Therapeutics, Inc. Common Stock (SION) holds total assets worth $325.95 Million USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see SION market cap overview for the company's overall valuation and market capitalisation.
Total Assets of Sionna Therapeutics, Inc. Common Stock (2022–2025)
Total assets of Sionna Therapeutics, Inc. Common Stock from 2022 to 2025. This chart illustrates how Sionna Therapeutics, Inc. Common Stock's total assets have evolved over time, based on quarterly financial data. See SION live share price for real-time trading data and today's change.
Sionna Therapeutics, Inc. Common Stock - Asset Composition Analysis
Sionna Therapeutics, Inc. Common Stock Total Assets Breakdown (December 2025)
Sionna Therapeutics, Inc. Common Stock total assets breakdown as of December 2025. Sionna Therapeutics, Inc. Common Stock's total assets of $325.95 Million consist of 74.1% current assets and 25.9% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 17.9% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2022–2025)
This chart illustrates how Sionna Therapeutics, Inc. Common Stock's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Sionna Therapeutics, Inc. Common Stock short-term liquidity ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Sionna Therapeutics, Inc. Common Stock's current assets represent 74.1% of total assets in 2025, a decrease from 96.0% in 2022.
- Cash Position: Cash and equivalents constituted 17.9% of total assets in 2025, down from 62.8% in 2022.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2022.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Sionna Therapeutics, Inc. Common Stock Competitors by Total Assets
Key competitors of Sionna Therapeutics, Inc. Common Stock based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Verona Pharma plc
F:I9SA
|
Germany | €572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.46 Billion |
|
Metsera, Inc. Common Stock
NASDAQ:MTSR
|
USA | $639.66 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Bavarian Nordic
CO:BAVA
|
Denmark | Dkr14.95 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
Sionna Therapeutics, Inc. Common Stock - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 20.61 | 14.49 | 4.88 |
| Quick Ratio | 20.61 | 14.49 | 4.88 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $229.71 Million | $140.57 Million | $31.17 Million |
Sionna Therapeutics, Inc. Common Stock - Advanced Valuation Insights
This section examines the relationship between Sionna Therapeutics, Inc. Common Stock's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 5.94 |
| Latest Market Cap to Assets Ratio | 0.51 |
| Asset Growth Rate (YoY) | 75.5% |
| Total Assets | $325.95 Million |
| Market Capitalization | $167.84 Million USD |
Valuation Analysis
Below Book Valuation: The market values Sionna Therapeutics, Inc. Common Stock's assets below their book value (0.51x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Sionna Therapeutics, Inc. Common Stock's assets grew by 75.5% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Sionna Therapeutics, Inc. Common Stock (2022–2025)
The table below shows the annual total assets of Sionna Therapeutics, Inc. Common Stock from 2022 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $325.95 Million | +75.48% |
| 2024-12-31 | $185.75 Million | +257.59% |
| 2023-12-31 | $51.95 Million | -40.55% |
| 2022-12-31 | $87.37 Million | -- |
About Sionna Therapeutics, Inc. Common Stock
Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109,… Read more